2020年5月29日星期五（健康日常新闻） - 对于具有晚期前列腺癌的男性，口服促性腺激素 - 释放激素（GNRH）拮抗剂Relugolix与GnRH激动剂血亮丙醇相比，依甲醛酰胺与非更换性的增生与安慰剂相关的睾酮抑制保持睾酮抑制，抗阉割的前列腺癌，根据5月29日在线发布的两项研究新英格兰医学杂志与美国临床肿瘤学会虚拟科学计划一致。
Neal D. Shore, M.D., from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and colleagues randomly assigned patients with advanced prostate cancer to receive relugolix (orally once daily) or leuprolide (injections every three months) for 48 weeks (622 and 308 patients, respectively). The researchers found that 96.7 and 88.8 percent of men receiving relugolix or leuprolide, respectively, maintained castration (sustained testosterone suppression to castrate levels) through 48 weeks. The difference indicated noninferiority and superiority of relugolix. The superiority of relugolix over leuprolide was also demonstrated in all other key secondary end points.
Cora N. Sternberg, M.D., from Weill Cornell Medicine in New York City, and colleagues conducted a double-blind study in which men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen level who were receiving androgen-deprivation therapy were randomly assigned to receive enzalutamide or placebo (933 and 468 patients, respectively). The researchers found that median overall survival was 67 and 56.3 months in the enzalutamide and placebo groups, respectively (hazard ratio for death, 0.73).
岸上研究由医学科学资助;Sternberg研究由辉瑞和阿斯特拉斯制药公司提供资金。摘要/全文 - 岸（可能需要订阅或付款）